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ABSTRACT
Psychological comorbidities and psychosocial challenges are prevalent among children and
adolescents with Inflammatory Bowel Disease (IBD). However, a comprehensive review of the
availability and effectiveness of psychological treatments for pediatric IBD patients is lacking.
This systematic review aimed to determine the availability and efficacy of psychological
interventions for children and adolescents with IBD. The systematic review was conducted in
accordance with PRISMA guidelines and performed using two electronic databases, PsycINFO
and PubMed, from inception until March 2022. Databases were searched for English-language,
controlled trials of psychological interventions for children and adolescents with IBD. Outcomes
of interest included: depression, anxiety, health-related quality of life, physical/somatic
symptoms, and disease activity/severity. Of 478 identified articles, 11 articles reporting on seven
original intervention studies met inclusion criteria. All interventions were cognitive-behavioral in
nature and drew from principles of cognitive-behavioral therapy (CBT). Clinical and
methodological diversity was observed across trials. Majority of trials included small sample
sizes and were underpowered, with four recruiting fewer than 50 participants. Some benefits
were reported in improving treatment outcomes, although findings were inconsistent. Despite an
established evidence-base for psychological interventions in other pediatric chronic illness
populations, evidence of efficacy for children and adolescents with IBD was limited.
Interventions tested in methodologically robust trials are needed to enhance the provision of
psychological treatments for pediatric IBD patients.

Keywords: Inflammatory Bowel Disease, pediatric, psychological intervention

Chapter 1: Introduction
Statement of the Problem
Inflammatory bowel disease (IBD) is a lifelong illness characterized by chronic
inflammation of the gastrointestinal tract. Studies have shown that children and adolescents with
IBD are at increased risk for emotional and behavioral difficulties (Mackner et al., 2013). Youth
with IBD were found to have higher rates of psychological comorbidities with clinical
depression rates up to 25%, in addition to lower health-related quality of life and social
functioning in comparison to healthy peers and youth with other chronic illnesses (Greenley et
al., 2010; Loftus Jr. et al., 2011; Ross et al., 2011). As such, psychological interventions have
been recommended for pediatric IBD patients that present with reported symptoms.
Evidence of the efficacy of psychological interventions has been well-studied in adults
with IBD; however, research appears limited regarding the efficacy of such treatments for youth
with IBD. A Cochrane review from 2011 evaluated the effectiveness of psychological treatments
for IBD with a primary focus on adult studies and included only two studies with pediatric
populations (Timmer et al., 2011). Although limited, the results of the review indicated that
adolescents with IBD may benefit from engaging in cognitive-behavioral therapy (CBT) with
improvements found in quality of life, coping skills, and psychological symptoms. The narrow
scope of this previous review precludes firm conclusions regarding the availability and efficacy
of psychological interventions for pediatric IBD patients. However, research has grown in this
area over the past decade, with increasing numbers of psychological intervention outcome
studies for pediatric IBD patients. The present systematic review aims to determine the
availability and efficacy of psychological interventions for children and adolescents with IBD.
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Background
Inflammatory bowel disease (IBD) comprises a group of chronic inflammatory
gastrointestinal disorders characterized by gastrointestinal inflammation and unpredictable
periods of disease activity and remission (Dubinsky, 2008). There are two primary subtypes of
IBD, Crohn’s disease (CD) and ulcerative colitis (UC), which differ in anatomical location and
nature of the inflammation. CD may involve the entire gastrointestinal tract, while UC involves
solely the large intestine. The diagnosis of indeterminate colitis (IC) is used in cases in which the
disease presentation cannot be clearly defined as CD or UC. IBD is estimated to affect over 3
million people in the United States, 2.5 to 3 million people in Europe, with a rising incidence in
Asia (Burisch et al., 2013; Dahlhamer et al., 2016; Mak et al., 2020). IBD has been found among
all races and ethnic groups (Loftus Jr., 2004). Historically, Caucasians were found to have higher
incident rates of IBD; however, rates have been increasing among African American/Black and
Latinx populations (Barnes et al., 2017). Approximately 25% of patients with IBD present before
adulthood, with peak onset in adolescence (Abramson et al., 2010). The incidence of pediatric
IBD is approximately 10 per 100,000 children with a prevalence of 100 to 200 per 100,000
children in the United States (Kappelman et al., 2013).
Common symptoms of IBD include abdominal pain, diarrhea, bloody stools, rectal
bleeding, fecal incontinence and/or bowel urgency, fatigue, loss of appetite/food avoidance, and
weight loss. In children and adolescents, growth failure and delayed pubertal development is
common (Rabizadeh & Dubinsky, 2013). IBD patients are also at a higher risk of developing
colorectal cancer in comparison with the general population (Kim & Chang, 2014). In addition,
IBD with pediatric onset is often more extensive at time of presentation and undergoes continued
progression within the first five to seven years following diagnosis (Szigethy et al., 2010).
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The cause of IBD is not yet understood, although research has attributed it to an
interaction between genetic predisposition, immune system disturbance, and environmental
triggers (Rosen et al., 2015). IBD has remained an incurable disease with medical treatment
focused primarily on symptom management to achieve and maintain symptom remission and
improve quality of life. In times of disease flares/relapses, urgent medical treatment may be
required. During periods of disease remission, patients may still experience painful and
distressing gastrointestinal symptoms due to the development of visceral hypersensitivity or
comorbid irritable bowel syndrome (Grover et al., 2009). Management of IBD symptoms
typically involve a complex, time-consuming, and potentially burdensome treatment regimen
consisting of multiple medication doses per day, infusions, dietary modifications, and in severe
cases, surgery (Carter et al., 2004; Mowat et al., 2011). High-dose steroids are often utilized in
treatment which elicit negative side-effects such as facial swelling, weight gain, acne, hair
growth, and emotional lability (Greenley et al., 2010). Moreover, invasive medical procedures
can result in traumatization and reactions ranging from dissociation, anxiety, and frustration,
which can impact treatment and disease progression (Szigethy et al., 2010).
IBD often has an impact on more than just the gastrointestinal tract, as patients with IBD
endorse elevated levels of emotional distress and higher rates of psychological comorbidities
such as depression and anxiety diagnoses (Kappelman et al., 2014; Mikocka-Walus et al., 2016).
Research has found that these psychological comorbidities have been negatively associated with
psychological well-being and disease-related outcomes in IBD populations including lower
quality of life, increased perceived stress, IBD relapse, inflammation, pain, poor medication
adherence, and increased risk of surgery (Goodhand et al., 2012; Gray et al., 2012; Greenley et
al., 2010; Regueiro et al., 2017). In pediatric IBD populations, high rates of anxiety and
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depression have been found and youth with IBD have a higher risk of developing clinical
depression and anxiety compared to youth with other chronic illnesses and healthy peers
(Greenley et al., 2010; Mikocka-Walus et al., 2016). Youth with IBD are also at risk for lower
quality of life and social functioning compared to healthy peers (Greenley et al., 2010; Loftus Jr.
et al., 2011; Ross et al., 2011).
Current Theory and Research
There are a multitude of psychosocial challenges that pediatric IBD patients may face as
a result of their illness. Diagnosis of IBD in both childhood and adolescence can involve a sense
of loss of independence, control, and privacy, as well as impact one’s body image, peer
relationships, self-confidence, and productivity (Szigethy et al., 2010). In childhood, the
unpredictable and stigmatizing symptoms of IBD may negatively impact a child’s social
development (Greenley et al., 2010). Frequent bathroom visits and unexpected disease flares
create difficulties for children with IBD to attend social activities which can negatively impact
peer-relationships and increase social isolation. These children may fear being the target of
“bathroom humor,” limit their social activities, and need to unexpectedly cancel plans due to
disease flares (Greenley et al., 2010). Similarly, adolescents with IBD face significant
psychosocial challenges related to their illness (Stapersma et al., 2019). Adolescence is a life
phase characterized by changes in biological, psychological, social, and academic domains.
Having a chronic disease such as IBD and its burdensome medical treatment may severely
impact psychosocial functioning and quality of life in pediatric IBD patients.
Psychological Functioning
A number of studies have found that pediatric IBD patients are at-risk for developing comorbid depression and anxiety disorders, with high prevalence rates varying from 20-50% for

5
depression and anxiety (Clark et al., 2014; Kilroy et al., 2011; Reigada et al., 2015a; Szigethy et
al., 2014a). In a large study involving pediatric IBD patients, Loftus Jr. and colleagues (2011)
found that children with IBD were at greater risk for developing depressive and anxiety disorders
in comparison to healthy peers and that the utilization of steroids was a risk factor for developing
such disorders. Studies conducted by Mackner & Crandall (2005; 2006) found that adolescents
with IBD have a 4.6 times increased risk of having clinically significant symptoms of depression
and anxiety in comparison to healthy peers. Hommel and colleagues (2008) found that 18.524.5% of their sample of youth with IBD exceeded the clinical cut-off for depression on
validated assessment measures. Among the studies conducted that utilized a control group,
depression and anxiety were found to be considerably higher among youth with IBD than control
groups of healthy peers without chronic medical conditions (Greenley et al., 2010). These rates
are comparable to other pediatric chronic illness populations such as cystic fibrosis, diabetes, and
cancer, although rates of lifetime depression have been higher in those with IBD in comparison
to individuals with cystic fibrosis (Burke et al., 1989; Greenley et al., 2010).
The unpredictable nature of the disease course, as well as the invasive and embarrassing
symptoms involved, place pediatric IBD patients at increased risk for developing depressive
symptoms (Greenley et al., 2010; Mackner et al., 2006; Reed-Knight et al., 2018). Furthermore,
Szigethy and colleagues (2014a) found three distinct profiles of depression in their sample of
youths with IBD. These three profiles included mild depression, categorized by low-grade
depressive symptoms; somatic depression, characterized by severe fatigue, anhedonia, depressed
mood, changes in appetite, and reduced motor activity; and cognitive despair, differentiated by
individuals having the highest severity of self-reported depressive symptoms including suicidal
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ideation (Szigethy et al., 2014a). Thus, subgroup-specific interventions may be needed to
optimize depression treatment options in youth with IBD.
Given the increased risk for depressive symptoms in pediatric IBD patients, researchers
have recently explored the relationship between prominent features of IBD and depressive
symptoms. Studies have found that youth-perceived IBD stigma is a significant predictor of
depressive symptoms and that youth who perceive greater uncertainty associated with their IBD
are more likely to experience increased depressive symptoms (Baudino et al., 2019; Gamwell et
al., 2018; Roberts et al., 2019). Research suggests that the unpredictability of living with IBD in
addition to IBD-related stigma are associated with youth depressive symptoms (Gamwell et al.,
2020).
Several studies have found that disease severity, which includes disease activity and pain,
has an impact on mental health and well-being (Mackner & Crandall, 2007). In studies that
found an effect, pediatric IBD patients who endorsed greater disease activity and pain reported
poorer mental health and well-being in comparison to pediatric IBD patients in remission (Perrin
et al., 2008). In a study conducted by Szigethy and colleagues (2014a), depressed youth with
IBD reported greater disease activity than non-depressed individuals with IBD. Persoons and
collaborators (2005) also found decreased remission rates in individuals with major depressive
disorder. Other studies have not found such an effect, suggesting that while disease severity
accounts for a small amount of variation in reports of well-being and mental health, additional
factors are important to consider (Reed-Knight et al., 2016).
In addition to psychological comorbidities, short-term and long-term stress may
negatively impact the course of IBD. Research regarding the gut-brain axis has been emerging,
which suggests bidirectional communication between the gut and brain (Abautret-Daly et al.,
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2018). Due to the bidirectionality of the gut-brain axis, psychological stress and/or psychological
symptoms may, in turn, exacerbate IBD symptoms (Abautret-Daly et al., 2018). Some
researchers have hypothesized that stress may be a risk factor for relapse in IBD patients.
Langhorst and colleagues (2013) found that short-term stress, as opposed to long-term stress,
was predictive of relapse in IBD patients with UC. However, the link between stress and IBD
remains a controversial topic in the field and requires further study, due to some studies reporting
no effect of stress on the development of IBD or risk of relapse (Li et al., 2004; Vidal et al.,
2008). While increased risk of psychological symptoms during active IBD is generally agreed
upon in the field, research is limited on the prevalence of psychological symptoms during disease
remission (Abautret-Daly et al., 2018).
Health-Related Quality of Life & Coping
Health-related quality of life (HRQOL) is a concept that refers to one’s perceived quality
of physical, mental, emotional, and social functioning (Stapersma et al., 2019). HRQOL in
children and adolescents with IBD has been found to be significantly lower in comparison to
healthy peers (Knowles et al., 2018; Ross et al., 2011). Primary concerns related to HRQOL
identified by pediatric IBD patients include pain, frequent school absences, lack of energy, need
for medication, flare-ups, and having a lifelong condition (Mackner et al., 2004).
Additionally, other psychological factors such as illness perceptions (i.e., cognitive and
emotional representations of one’s disease) and coping (i.e., intentional efforts for cognitive and
behavioral regulation) have been shown to be related to psychosocial outcomes, such as
HRQOL, general functioning, and adjustment to IBD (Stapersma et al., 2019). Cognitive coping
has been found to be a key component in the etiology and maintenance of anxiety and
depression, particularly for youth with IBD (Mackner et al., 2004).
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The Common Sense Model (CSM) developed by Diefenbach and Leventhal (1996)
describes the relationship between disease characteristics, illness perceptions, coping, anxiety,
depression, and HRQOL. This model proposes that illness characteristics lead to specific illness
perceptions, which then influence the type of coping one utilizes to manage symptoms.
Subsequently, these factors lead to positive or negative illness outcomes such as depression,
anxiety, and lower HRQOL. Research has found several relationships between these variables in
IBD patients, although most studies have been conducted in adult populations. A systematic
review conducted by Brooks and colleagues (2016) that focused on pediatric IBD patients
demonstrated that negative illness perceptions were associated with more psychological
problems. In addition, coping was found to be a predictor of depression in youth with IBD (Van
Tilburg et al., 2015). Stapersma and colleagues (2019) found that negative illness perceptions
and depression were significantly associated with lower HRQOL in adolescent IBD patients.
Social & Academic Functioning
Late childhood and adolescence are significant transitional stages throughout various
aspects of cognitive, emotional, and social domains, which also correspond with peak age of
onset in pediatric IBD (Mackner et al., 2013). The emergence of a chronic illness such as IBD
can negatively influence typical development, resulting in a range of challenges with
psychosocial adjustment as well as attainment of developmental milestones and functional
growth. Given the chronic, complex, unpredictable, and embarrassing nature of IBD, pediatric
IBD patients are at increased risk for significant psychosocial maladjustment, particularly for
children who endure more aggressive treatment options (Gray et al., 2011; Mackner & Crandall,
2007). Pediatric IBD patients’ overall adjustment varies based on disease factors such as disease
activity/course (e.g., chronic non-remitting versus remission) and treatment (e.g., high-dose
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steroids, surgery). In addition to disease factors, individual differences in cognitive capacity,
emotional self-regulation ability, and behavioral impulse control can influence a child’s coping
style and adjustment to illness.
Youth with IBD report social problems more frequently than healthy peers, with
researchers hypothesizing that challenges with social relationships may be a significant predictor
of mental health problems (Mackner & Crandall, 2007). IBD is susceptible to condition-related
stigma, given that most cultures endorse a social taboo toward bowel symptoms (Saunders,
2014). As such, individuals with IBD report high levels of shame and embarrassment associated
with their condition (Defenbaugh, 2013). Youth with IBD often withdraw from social
interactions out of fear of experiencing abdominal pain, bowel noises, fecal incontinence and/or
bowel urgency in public. Shame and embarrassment further lead individuals to attempt to
conceal their illness which have been associated with reduced engagement with others, feelings
of disconnection, and negative affect (Kaushansky et al., 2017; Saunders, 2014). A study
conducted by Roberts and colleagues (2020) showed that difficulty communicating about one’s
illness to others was associated with thwarted belongingness which was linked to increased
depression. Pediatric IBD patients are at increased risk of internalizing stigmatized beliefs,
heightened shame, and lowered social self-efficacy, which can negatively impact mental health
outcomes (Kaushansky et al., 2017).
Furthermore, a diagnosis of IBD during childhood or adolescence significantly impacts
school functioning (Plevinsky et al., 2020). Pediatric IBD patients report increased school
absences due to clinic visits, hospitalizations, and active disease symptoms, as well as difficulties
with academic performance and social adjustment (Carreon et al., 2018). In a study conducted by
Moody and colleagues (1999), researchers found that 60% of their sample of children with
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moderate-to-severe IBD averaged three months of absences during the previous year and 80%
felt that they had underachieved due to ill health. Additionally, children with chronic health
conditions are at increased risk for peer victimization due to perceived differences from healthy
peers (Storch & Masia-Warner, 2004). These differences such as frequent bathroom use,
medication intake during school, school absences, changes in appearance (e.g., medication
induced facial swelling, acne, weight loss/gain), short stature, pubertal delay, restricted diets, and
limited ability to participate in normative social activities, may draw adverse attention from peers
(Mackner et al., 2006). In addition, youth with IBD often experience lower grade point averages
and poorer educational outcomes in comparison to their healthy peers (Mackner et al., 2012;
Singh et al., 2015). Older adolescents experiencing severe disease hold the greatest risk for
impaired academic functioning (e.g., attendance, academic performance), which may negatively
impact transitions to higher education/college (Carreon et al., 2018).
Rationale and Relevance to Practice
There has been increasing support for the use of adjunctive psychological interventions to
treat psychological comorbidities and disease-specific unmet clinical needs in chronically ill
populations. While the efficacy of psychological interventions has been well-studied in adults
with IBD, research appears limited regarding the efficacy of such treatments for youth with IBD.
Due to the multitude of psychosocial challenges presented in pediatric IBD, a greater
understanding of the effective psychological interventions available for this population is in
critical need. Thus, the present systematic review aims to determine the availability and efficacy
of psychological interventions for children and adolescents with IBD.

11
Research Questions
The research questions addressed in this review were: What are the available
psychological interventions for pediatric IBD patients? Of the available interventions, which are
the most effective in improving treatment outcomes? The primary treatment outcomes reviewed
included depression, anxiety, and health-related quality of life. Secondary treatment outcomes
consisted of physical/somatic symptoms, and disease activity. This review examined sample
characteristics, intervention characteristics, and outcomes with the hope of furthering the
literature regarding the availability and efficacy of psychological interventions for pediatric IBD
patients.
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Chapter 2: Methods
Systematic Review Approach
A systematic review was conducted to evaluate the current available quantitative research
on psychological interventions for pediatric IBD patients. A narrative synthesis framework was
utilized to report findings. Given the heterogeneity in study design and outcome assessments,
results from individual studies were not able to be meaningfully pooled for group analysis; thus,
precluding the use of a meta-analysis. As such, a narrative synthesis was most appropriate given
the state of the field to summarize findings of included studies supported by evidence tables.
This systematic review was carried out in accordance with the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) statement guidelines (Page et al., 2021).
Eligibility Criteria
The inclusion and exclusion criteria for the systematic review were identified based on
the research questions and the extensive literature review presented above. Eligible studies were
defined as studies of interventions that are primarily psychological in nature targeting pediatric
IBD patients. Studies must have been published in peer-reviewed journals and results of the
intervention must have been described in the included studies. Given that the efficacy of
psychological interventions for pediatric IBD has not been adequately examined, randomized
controlled trials (RCTs) and nonrandomized controlled trials (NRCTs) were included in this
review. Uncontrolled and qualitative studies were excluded as they are prone to subjectivity and
results may not be generalizable. The full text of selected studies must have been written in
English.
Participants of interest were pediatric patients (< 21 years) diagnosed with IBD
(diagnosed according to clinical, radiologic, endoscopic, or histological criteria). Studies that
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included mixed participant groups were included if the results were reported separately for IBD
patients, or if more than 50% of the participants had IBD. Studies that included both children and
adults were excluded, unless there was a separate analysis for the pediatric age group.
Included studies must have evaluated a psychological intervention. Psychological
interventions were defined as any intervention based on (a) specific psychological principles,
skills, or techniques, (b) a psychological theory, or (c) input from a mental health professional,
delivered in isolation or in conjunction with other physical, practical, or educational components.
Interventions that focused on bio-behavioral strategies (e.g., relaxation, hypnosis, biofeedback,
mindfulness) were also considered for inclusion. Interventions delivered individually (with or
without a parent-component), in a group-setting, or in a family context were also considered for
inclusion. Studies must have gathered quantitative data utilizing outcome measures that assessed
for psychological outcomes (e.g., depression, anxiety), HRQOL, physical/somatic symptoms
and/or disease activity/severity. Studies that did not evaluate an intervention were excluded.
The primary goal of psychological interventions for the treatment of pediatric IBD is to
reduce associated psychological symptoms (e.g., depression, anxiety), improve quality of life,
decrease physical/somatic symptoms, and/or reduce disease activity/severity. Given that
pediatric IBD patients are at increased risk for developing psychological comorbidities and lower
quality of life, (a) depression, (b) anxiety, and (c) HRQOL were chosen as the primary outcomes
as defined by scores on validated self- or caregiver-reported questionnaires and/or
structured/semi-structured clinical interviews. Secondary outcomes included physical/somatic
symptoms, and disease activity. Studies that did not measure primary or secondary outcomes
were excluded. Additionally, studies that did not utilize validated instruments to measure
outcomes were excluded.
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Search Strategy
A comprehensive search was performed using two electronic databases, PsycINFO and
PubMed, from inception to March 30, 2022. Searches were limited to peer-reviewed and
English-language studies. Search terms used included inflammatory bowel disease, pediatric, and
intervention. Synonyms for these search terms and full search strategy can be found in the List of
Search Terms and Search Strategy chart (See Appendix B). The list of terms was selected based
on a preliminary review of the literature, preliminary searches using various search strategies,
and a brief pilot of data extraction methods. Relevant variations and combinations of search
terms in the databases and MeSH terms were used. An example of these combinations included
“Inflammatory bowel disease OR Crohn’s disease OR ulcerative colitis” AND “pediatric OR
child OR adolescent OR youth” AND “intervention OR treatment OR training OR therapy.” See
the Results section for details (e.g., number of records) from each database search.
Screening Process
Following database searches, each result was initially screened to determine eligibility.
First, the title and abstract of each article was reviewed to determine whether the scope of the
research variables was included. Unrelated articles or articles that did not focus on psychological
interventions in pediatric IBD were excluded. Next, the full texts of remaining articles were read
and screened for all inclusion and exclusion criteria to assess for eligibility. A spreadsheet was
designed to record the results of the screening and selection process (see Appendix C for
Screening and Selection Record). The PRISMA Flow Diagram (See Figure. 1) depicts the flow
of sources from one phase of the systematic review to the next. It begins with a total number of
records identified through database searches, then the total number of sources after duplicates
were removed. Next, it states the number of articles that were screened via title and abstract for
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eligibility and the number of articles that were excluded in that process. It then shows the
number of sources where the full text was assessed for eligibility, and the number of studies that
were excluded in that process accompanied by the reason for their exclusion. Finally, the
diagram ends with the total number of studies included in the systematic review.
Data Collection and Extraction
Data from eligible studies was collected through a careful review of each selected study
and stored in an excel spreadsheet (see Appendix D for Data Collection and Extraction
Spreadsheet). The data collection and extraction spreadsheet was informed by various published
data extraction forms. The specific variables chosen to be extracted were based on relevant
information related to the research questions as well as a preliminary search of the research on
psychological interventions for pediatric IBD. The data collection spreadsheet was organized by
several categories: (a) General Information, (b) Design Characteristics and Methodological
Features, (c) Sample Characteristics, (d) Intervention Characteristics, (e) Outcome
Measures/Impact of Treatment, (f) Main Findings and Conclusions, (g) Limitations of the Study,
and (h) Recommendations for Future Research. A section for additional notes was included
within the categories for information that may be important but could not be obtained by the preidentified extraction category. The data collection spreadsheet included the following columns in
the presented order: Date of Extraction, Article I.D., In-text Citation, APA Citation, Study Aims,
General Methodology, Study Design, Setting, Country, Sample Size, Age, Gender,
Race/Ethnicity, Illness Type, Disease Severity, Age at Diagnosis, Time since Diagnosis,
Theoretical Framework or Therapeutic Orientation, Intervention Format (e.g., group or
individual), Caregiver/Parental Involvement, Number of Sessions, Frequency of Sessions,
Duration of Treatment, Mode of Delivery, Intervention Group, Control or Comparison Group,
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Intervention Components, Outcomes and Measurements: Depression, Outcomes and
Measurements: Anxiety, Outcomes and Measurements: Health-related Quality of Life
(HRQOL), Outcomes and Measurements: Physical/Somatic Symptoms, Outcomes and
Measurements: Disease Activity/Severity, Time Points Assessed, Main Findings, Limitations,
and Recommendations. Following data extraction, categories were developed based on what the
authors provided and were described in the results section.
Risk of Bias and Quality Appraisal Methods
The quality of the chosen studies was assessed using a Quality Appraisal Form (see
Appendix E for the Quality Appraisal Form) designed by the university’s program research
coordinator and modified by the researcher. The researcher evaluated each selected article with
the Quality Appraisal Form to determine the overall quality of the literature used within the
systematic review. The Quality Appraisal Form evaluated the following criteria: (a) Strength of
literature foundation and rationale for study, (b) Clarity and specificity of research aims, (c)
Quality of research design or methodological approach, (d) Sample selection and characteristics,
(e) Data collection tools, (f) Data collection processes, (g) Analysis and presentation of data, (h)
Discussion of study limitations, and (i) Consideration of culture and diversity. Each item was
scored on a scale ranging from weak (1) to strong (3) with the option of inapplicable (NA). The
rating for each of the above-mentioned components was used to obtain an overall rating of a
study’s quality. Exemplary quality scores were considered for studies that received a score
consisting of all 3’s, Strong quality scores consisted of mostly 3’s, Good/Adequate quality scores
consisted of mostly 2’s, and Weak quality scores consisted of mostly 1’s.
Given that the aim of this systematic review was to gather information about the
availability and efficacy of psychological interventions for pediatric IBD patients, there was risk
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of bias during the review and extraction process on part of the researcher. To minimize bias in
the selection of studies, the quality appraisals were conducted after the data had been extracted.
Following the completion of the quality appraisal process, findings were synthesized to provide a
narrative conclusion on the overall caliber of the literature used in the systematic review.
Furthermore, the results of this analysis helped form the basis of the recommendations and
limitations of the review.
Data Management, Synthesis, and Analysis Methods
Following the completion of data collection and extraction, the collected data were
organized and presented in three data tables. During the organization process, data were
categorized and put into a consistent format. These tables were used as the evidence base for the
research questions. Table 1. Study and Participant Characteristics presents data related to study
design, sample characteristics, and demographic data from each of the included studies. Table 2.
Intervention Characteristics presents information related to the availability of interventions as
well as pertinent intervention components. Table 3. Treatment Outcomes and Main Findings
presents information on the assessed outcomes, measuring instruments, and main findings of
each included study.
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Chapter 3: Results
Search Results
The final search yielded a result of 478 articles (PsycInfo: n = 241, PubMed: n = 237).
Once duplicates were removed (n = 10), 468 articles were screened for eligibility, which
included reviewing the title and abstract for relevancy. This resulted in the exclusion of 429
articles, with 39 full-text articles sought for retrieval. All full texts of the 39 articles were
retrieved and assessed for eligibility based on inclusion and exclusion criteria. Of those articles,
28 were excluded due to being uncontrolled studies (n = 8), not assessing primary or secondary
outcomes (n = 8), only including adult samples (n = 6), only including parents of children with
IBD (n = 3), and not including separate analyses for the pediatric age group in studies that
included both adolescents and young adults (n = 3). After full text screening for inclusion
criteria, a total of 11 articles of which seven reported on original intervention studies were
included in the systematic review. The remaining four articles reported on longitudinal results of
the included original studies. Therefore, data from the four articles were extracted and included
with the results of their respective original study. See Figure 1. PRISMA Flow Diagram for
further details.
Study Population Characteristics
Majority of studies were conducted in the United States of America (n = 5; Levy et al.,
2016; McCormick et al., 2010; Reigada et al., 2015b; Szigethy et al., 2007; Szigethy et al.,
2014b). Remaining studies were conducted in the Netherlands (n = 2; Grootenhuis et al., 2009;
Stapersma et al., 2018). Five were randomized controlled trials (RCTs; Levy et al., 2016;
Reigada et al., 2015b; Stapersma et al., 2018; Szigethy et al., 2007; Szigethy et al., 2014b) and
two were non-randomized controlled trials (NRCTs; Grootenhuis et al., 2009; McCormick et al.,
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2010). Control conditions included treatment as usual (TAU; Stapersma et al., 2018; Szigethy et
al., 2007), education support (Levy et al., 2016), supportive non-directive therapy (SNDT;
Reigada et al., 2015b; Szigethy et al., 2014b), and wait-list control groups (Grootenhuis et al.,
2009; McCormick et al., 2010). Sample sizes of included studies ranged from 22 to 217.
Majority of trials were small, with four recruiting fewer than 50 participants (Grootenhuis et al.,
2009; McCormick et al., 2010; Reigada et al., 2015b; Szigethy et al., 2007). Mean age ranged
from 13.2 to 15.7 years. Majority of trials had an even gender distribution, except for two
studies, one which consisted of 68.6% females (Stapersma et al., 2018) and the other which
recruited females only to ensure a homogenous group (McCormick et al., 2010). All but one
study (Grootenhuis et al., 2009) provided information on ethnicity/race. Of these studies, all had
samples with 68% or more self-identified White/Caucasian participants (ranged from 68.2% to
94.6%).
All but one study (Reigada et al., 2015b) reported separately for IBD subtypes, in which
the proportions with Crohn’s disease (CD) ranged from 51.4% to 74.2%, ulcerative colitis (UC)
from 22% to 37.2%, and indeterminate colitis (IC) from 7.5% to 12.5%. Of those studies, all
samples had a higher rate of participants with Crohn’s disease in comparison to the other two
disease subtypes. Four of the studies reported on disease severity at baseline (Levy et al., 2016;
McCormick et al., 2010; Stapersma et al., 2018; Szigethy et al., 2007). Severity rates ranged
from 50% to 75.5% for remission, 24.3% to 29% for mild, and 8.2% to 29% for moderate to
severe. Of those studies, majority of their samples were in remission at baseline. One trial
recruited only participants who had comorbid IBD and an anxiety disorder (Reigada et al.,
2015b) and two trials recruited participants with IBD who met criteria for mild to moderate
depression (Szigethy et al., 2007; Szigethy et al., 2014b). One study recruited participants who
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only had subclinical anxiety and/or depressive symptoms (Stapersma et al., 2018). See Table 1.
Study and Participant Characteristics for details.
Intervention Availability
All of the studies evaluated interventions that were cognitive-behavioral in nature and
drew from principles of cognitive-behavioral therapy (CBT), emphasizing the interrelationship
between thoughts, feelings, behaviors, and physiology. Sessions ranged from three to 13 weekly
sessions. All but one study included parental involvement in their interventions (Grootenhuis et
al., 2009). One intervention held joint-sessions in which parents and children participated in the
sessions together (Levy et al., 2016). One intervention incorporated parents intermittently
throughout the session (e.g., parents were involved at the beginning and end of each session) in
addition to having separate parent sessions (Reigada et al., 2015b). Three interventions held
parent sessions separately from the child sessions (Stapersma et al., 2018; Szigethy et al., 2007;
Szigethy et al., 2014b). Majority of interventions were delivered in-person, with one intervention
being primarily virtual (e.g., one day in-person group workshop followed by six-weeks webbased skill review; Levy et al., 2016). Three interventions included a mix of in-person and
telephone sessions, although primarily included face-to-face sessions (Stapersma et al., 2018;
Szigethy et al., 2007; Szigethy et al., 2014b). Majority of the interventions utilized individualbased psychotherapy, while two studies utilized group interventions (Grootenhuis et al., 2009;
McCormick et al., 2010).
Four studies evaluated two manualized, empirically-based, health-sensitive cognitivebehavioral interventions that were adapted specifically for IBD patients with comorbid
psychological symptoms (e.g., depression, anxiety): Treatment of Anxiety and Physical
Symptoms for Inflammatory Bowel Disease (TAPS + IBD; Reigada et al., 2015b) and Primary
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and Secondary Control Enhancement Training for Physical Illness (PASCET-PI; Stapersma et
al., 2018; Szigethy et al., 2007; Szigethy et al., 2014b). Both interventions utilized an individual
psychotherapy format with parental involvement that ranged from nine to 13 weekly sessions.
TAPS + IBD was developed to concurrently treat anxiety (including IBD-specific anxiety) and
physical symptoms among pediatric patients with comorbid IBD and anxiety (Reigada et al.,
2015b). This treatment utilizes components such as relaxation, cognitive restructuring,
exposures, and homework exercises to target fears related to IBD-specific concerns and
symptom management in addition to general (non-disease related) anxiety and functional
physical symptoms. PASCET-PI is a disease-specific protocol developed for adolescents with
IBD and depression. In addition to behavioral activation, cognitive restructuring, and problemsolving skills, disease-specific components are also included in the intervention such as physical
illness narrative, disease-specific psychoeducation, techniques for pain and immune functioning,
social skills training, and emphasis on IBD-related cognitions and behaviors (Szigethy et al.,
2007).
Three additional skills-based cognitive-behavioral interventions were adapted for use
with IBD patients to promote adaptive coping (Grootenhuis et al., 2009; Levy et al., 2016;
McCormick et al., 2010), with two studies utilizing a group format (Grootenhuis et al., 2009;
McCormick et al., 2010) and two studies including parental involvement (Levy et al., 2016;
McCormick et al., 2010). Common components of these structured, skills-based interventions
included psychoeducation regarding the CBT model and coping skills, teaching of relaxation
skills, cognitive restructuring (e.g., identifying and changing maladaptive cognitions and
discouraging negative self-talk), active skill practice in session, and homework assignments to
reinforce the learned skills. See Table 2. Intervention Characteristics for details.
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Intervention Efficacy
To examine the efficacy of the reported interventions, information regarding primary and
secondary treatment outcomes and their respective measuring instruments were extracted from
each of the included studies. For the purposes of this study, primary outcomes included
depression, anxiety, and health-related quality of life (HRQOL). Secondary outcomes included
physical/somatic symptoms and disease activity/severity. All studies included in this systematic
review utilized validated assessment tools to measure treatment outcomes. All studies utilized at
least one outcome assessment that included both self- and parent-report. Three studies
incorporated semi-structured diagnostic clinical interviews in addition to assessment measures
(Reigada et al., 2015b; Szigethy et al., 2007; Szigethy et al., 2014b). See Table 3. Treatment
Outcomes and Main Findings for more details.
Depression
Five studies evaluated depression or depressive symptoms using validated symptombased measures (Grootenhuis et al., 2009; Levy et al., 2016; Stapersma et al., 2018; Szigethy et
al., 2007; Szigethy et al., 2014b). Among these studies, three showed significant findings
(Stapersma et al., 2018; Szigethy et al., 2007; Szigethy et al., 2014b). In a RCT conducted by
Szigethy and colleagues (2007), a disease-specific CBT intervention (i.e., PASCET-PI) was
conducted for pediatric patients with comorbid IBD and subsyndromal depression. Results
demonstrated that the CBT intervention was effective in reducing depressive severity but not for
the number of depressive symptoms immediately post-intervention (Szigethy et al., 2007). The
impact on depressive severity was not maintained at six- or 12-month follow-up (Thompson et
al., 2012). In a later RCT, the same disease-specific CBT intervention was effective in reducing
depressive symptoms, although outcomes were equally favorable to supportive non-directive
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therapy (SNDT; Szigethy et al., 2014b). There were no significant differences between the CBT
and SNDT groups in change over time and the trial did not include a treatment as usual control
group (Szigethy et al., 2014b). Stapersma and colleagues (2018) conducted a RCT to evaluate
the effectiveness of a disease-specific CBT protocol for IBD patients with subclinical anxiety
and/or depressive symptoms compared to a treatment as usual control group. The trial utilized
the same disease-specific CBT intervention that was originally developed to treat comorbid IBD
and depression (i.e., PASCET-PI), although tailored the intervention for participants with
anxiety. Participants in both the intervention and control groups improved in their symptoms of
depression, anxiety, and HRQOL, indicating that the intervention did not perform better than
standard medical care in improving depressive symptoms.
Anxiety
Four studies evaluated anxiety or anxiety-related symptoms using validated symptombased measures (Grootenhuis et al., 2009; Levy et al., 2016; Reigada et al., 2015b; Stapersma et
al., 2018). Of these studies, two trials showed significant findings (Reigada et al., 2015b;
Stapersma et al., 2018). In a RCT conducted by Reigada and colleagues (2015b), a diseasespecific CBT intervention (i.e., TAPS +IBD) was conducted for pediatric patients with comorbid
IBD and anxiety. Results demonstrated that the CBT intervention was effective in reducing IBDspecific anxiety post-treatment and at three-month follow-up. As mentioned above, Stapersma
and colleagues (2018) found that participants in both intervention and control groups improved
in their symptoms of anxiety, indicating that the intervention did not perform better than standard
medical care in improving anxiety symptoms.
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Health-Related Quality of Life (HRQOL)
Four studies evaluated health-related quality of life (HRQOL) using validated measures
(Grootenhuis et al., 2009; Levy et al., 2016; Stapersma et al., 2018; Szigethy et al., 2014b). Of
these studies, majority utilized the IMPACT-III questionnaire, a disease-specific HRQOL
measure developed for pediatric IBD (Levy et al., 2016; Stapersma et al., 2018; Szigethy et al.,
2014b). Among these studies, three found significant findings (Grootenhuis et al., 2009; Levy et
al., 2016; Stapersma et al., 2018). Grootenhuis and colleagues (2009) investigated the effects of a
psychoeducational group intervention for adolescents with IBD on coping and HRQOL. The
study detected a positive increase in the intervention group on a subscale of HRQOL (body
image), although no additional effects were found on other subscales of HRQOL (Grootenhuis et
al., 2009). Levy and colleagues (2016) conducted an RCT to evaluate the efficacy of a brief CBT
intervention for children with IBD and their parents. The study found a significant overall
treatment effect for child-reported IBD-specific quality of life (Levy et al., 2016). As mentioned
above, Stapersma and colleagues (2018) found that participants in both intervention and control
groups improved in their symptoms related to HRQOL, indicating that the intervention did not
perform better than standard medical care in improving HRQOL.
Physical/Somatic Symptoms
Two studies evaluated physical or somatic symptoms using validated symptom-based
measures (Levy et al., 2016; McCormick et al., 2010). These studies looked at varying aspects of
physical/somatic symptoms, including abdominal pain (McCormick et al., 2010), somatization
(McCormick et al., 2010), functional disability (Levy et al., 2016), and pain responses (Levy et
al., 2016). In a trial conducted by Levy and colleagues (2016), the intervention did not have a
significant effect on reducing symptoms of functional disability. Improvements over time on
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pain responses were found, although the improvements were similar between the two conditions.
A small coping skills intervention conducted by McCormick and colleagues (2010) found
significant improvements in adolescents’ somatic symptoms following treatment, although
between-group comparisons were not significant.
Disease Activity/Severity
Majority of studies included a measure for disease activity/severity (Levy et al., 2016;
Reigada et al., 2015b; Stapersma et al., 2018; Szigethy et al., 2007; Szigethy et al., 2014b). Each
of these studies included the Pediatric Crohn’s Disease Activity Index (PCDAI) for Crohn’s
disease patients, and either the Pediatric Ulcerative Colitis Activity Index (PUCAI) or the
Clinical Score of Kozarek (CSK) for ulcerative colitis patients. While all three validated
instruments include self-report on signs and symptoms of disease activity (e.g., abdominal pain,
diarrhea, well-being, functional disability), only the PCDAI includes physical/objective findings
and laboratory values. Of these studies, only one showed significant findings (Szigethy et al.,
2014b). The study found that participation in the disease-specific CBT intervention group was
associated with a greater reduction in disease activity over time in comparison to the SNDT
group (Szigethy et al., 2014b). Secondary analyses indicated that of the participants in the CBT
intervention group, patients with Crohn’s disease with a somatic depressive subtype and active
disease showed greater improvement in disease activity (Szigethy et al., 2015).

26
Chapter 4: Discussion
To our knowledge, this is the first systematic review to explore the availability and
efficacy of psychological interventions for children and adolescents with IBD. The review
identified seven controlled trials, which were all CBT-based interventions. Primary aims and
treatment outcomes varied across studies. Three skills-based CBT interventions aimed to
improve HRQOL and pain/somatic symptoms as a result of learning adaptive coping skills
(Grootenhuis et al., 2009; Levy et al., 2016; McCormick et al., 2010). The remaining four trials
primarily focused on improving psychological functioning through the reduction of depressive
and/or anxiety symptoms (Reigada et al., 2015b; Stapersma et al., 2018; Szigethy et al., 2007;
Szigethy et al., 2014b). These four studies evaluated two manualized, empirically-based, healthsensitive cognitive-behavioral interventions that were adapted specifically for IBD patients with
comorbid psychological symptoms (e.g., depression, anxiety): TAPS + IBD and PASCET-PI
(Reigada et al., 2015b; Stapersma et al., 2018; Szigethy et al., 2007; Szigethy et al., 2014b).
Overall, evidence of the efficacy of the seven identified psychological interventions was
inconsistent. Reigada and colleagues (2015b) found that the TAPS + IBD intervention was
associated with significantly greater reductions in IBD-specific anxiety. Szigethy and colleagues
(2007) found that the PASCET-PI intervention was associated with significantly greater
improvement in depression severity post-treatment, although improvement was not maintained
longitudinally. In a later study by Szigethy and colleagues (2014b), both PASCET-PI and SNDT
interventions resulted in significant reductions in depressive symptoms, although the difference
between the two treatments was not significant. However, findings from this study indicated that
PASCET-PI was associated with a greater reduction in disease activity, particularly for Crohn’s
disease patients with active disease and a somatic depressive subtype. Stapersma and colleagues
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(2018) found that participants in both the adapted PASCET-PI intervention group and TAU
control groups improved in their symptoms of depression and/or anxiety as well as HRQOL,
although no significant differences were found between groups. Levy and colleagues (2016)
found significant improvements in child-reported IBD-specific quality of life and pain responses,
although improvement of pain responses over time were similar between groups. It is important
to consider these findings while keeping in mind that majority of the studies excluded
participants with significant mental illness and active IBD. This resulted in enrollment of
participants with low baseline levels of psychological parameters, which may have made it more
difficult to demonstrate improvement.
The two NRCTs also found significant findings on reported treatment outcomes;
however, results should be interpreted with caution given methodological limitations.
Grootenhuis and colleagues (2009) found significant improvement in body image, a domain of
HRQOL, although no additional effects were found for other subscales of HRQOL. McCormick
and colleagues (2010) found significant improvements in somatic symptoms following treatment
in the intervention group, although between group comparisons were not significant. Despite
evidence of the efficacy of psychological interventions for other pediatric chronic conditions
(Thompson et al., 2011), the quality of the evidence for psychological interventions within
pediatric IBD was “weak” and evidence of efficacy inconsistent. Thus, intervention research is
urgently needed to strengthen the evidence base and inform mental health recommendations.
Limitations
Limitations of the current review include exclusive examination of English-language
trials, which may have precluded potential valuable studies published in other languages.
Furthermore, methodological limitations of the included studies generally rendered the current
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evidence base “weak.” Major limitations included use of small and underpowered samples and
study samples consisting of predominantly White/Caucasian participants in remission or with
mild disease activity. Thus, findings cannot be generalized to the larger patient population.
Additionally, trials that evaluated psychological functioning only included participants with
subclinical depression or anxiety, which may have led to lack of significant treatment effects and
potentially restricted the range of improvement on treatment variables. Interventions had
considerable diversity in terms of methods and components. Most trials used a standard care or
wait-list control; those incorporating an attentional control demonstrated discrepancies in process
(i.e., intervention duration, format), reducing the capacity to account for potential motivational
variables or nonspecific treatment effects. Additionally, the heterogeneity of outcomes made it
difficult to directly compare across trials.
Recommendations for Research and Practice
Given the multitude of psychological comorbidities and psychosocial challenges present
in children and adolescents with IBD, further empirical research into effective psychological
interventions is urgently needed. Future studies should be conducted that include more rigorous
methods, particularly prospective RCTs of protocolled interventions. Additionally, recruiting
samples with clinically significant psychological distress or active disease as well as examining
efficacy based on psychological and/or biological severity would also assist in assessing
differential intervention efficacy. Furthermore, searches conducted in this review did not render
any controlled trials on the efficacy of other types of psychological interventions with a biobehavioral focus (e.g., relaxation, stress management, mindfulness, hypnosis, biofeedback) for
pediatric IBD patients. Future research exploring the feasibility and efficacy of additional types
of psychological interventions among pediatric IBD patients is needed.
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In addition to implications for future research, this review highlights implications for
clinical practice. Majority of studies were conducted in medical settings, which supports the
feasibility and acceptability of screening for psychological symptoms as well as providing
psychosocial interventions for pediatric IBD patients in this setting. This allowed for increased
participant access to psychological services and the ability for providers to support patients in
times of medical crises. Integrating behavioral health strategies directly into medical settings as
well as tailoring treatment to be sensitive to increased disease activity seemed to be particularly
helpful when working with this specific population. Mental health providers working with
pediatric IBD patients are recommended to screen for depressive/anxiety symptoms, as these
symptoms can affect the disease course and quality of life. A flexible therapeutic approach
appears critical when working with youth with IBD given the unpredictable and relapsing nature
of the disease.
Conclusions
In sum, the evidence for the efficacy of psychological interventions for children and
adolescents affected by IBD was limited. Available evidence suggests positive treatment effects
of CBT-based, disease-specific psychological interventions for children and adolescents with
IBD. However, significant methodological limitations preclude firm conclusions regarding the
efficacy of psychological interventions for pediatric IBD. Thus, there is an urgent need for
methodologically robust trials to evaluate the efficacy of psychological interventions for
pediatric IBD patients.
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Tables
Table 1
Study and Participant Characteristics
Author
(Year)

Country

Study
Design

Sample
Size
Total
(n)

Gender
(%)

I = 22
C = 18
n = 40

Age
Range;
Mean
Age
(SD)
12-18;
15.5
(1.5)

Grootenhuis
et al. (2009)

Netherlands

NRCT

Levy et al.
(2016)

USA

RCT

I = 91
C = 94
n = 185

8-17;
13.5
(2.7)

F (47)
M (53)

White/Caucasian
(77.9)

McCormick
et al. (2010)
&
ReedKnight et al.
(2012)
Reigada et
al. (2015b)

USA

NRCT

I = 13
C = 11
n = 24

11-17;
14.5
(1.9)

F (100)

White/Caucasian
(91.7)
Black/African
American (8.3)

USA

RCT

I = 11
C = 11
n = 22

9-17;
13.2
(2.1)

F (59.1)
M
(40.9)

White/Caucasian
(68.2)
Multi-racial
(13.6)
Latino/Hispanic
(9.1)
Black/African
American (4.5)
Asian (4.5)
Dutch/Western
(78.5)

F (52.5)
M
(47.5)

Stapersma
et al. (2018)
&
Stapersma
et al. (2020)

Netherlands

RCT

I = 37
C = 33
n = 70

10-25*
17.69
(4.82)

F (68.6)
M
(31.4)

Szigethy et
al. (2007)
&
Thompson
et al. (2012)

USA

RCT

I = 22
C = 19
n = 41

11-17;
14.99
(2.01)

F (51)
M (49)

Ethnicity (%)

___

White/Caucasian
(78.1)
Black/African
American (14.6)
Latino/Hispanic
(2.4)
Unspecified
(4.9)

Disease
Type
(%)
CD
(70)
UC
(22.5)
IC (7.5)
CD
(68.6)
UC
(31.4)

CD
(54)
UC
(33.5)
IC
(12.5)
___

CD
(51.4)
UC
(37.2)
IC
(11.4)
CD
(70.7)
UC
(29.3)

Disease
Severity
(%)

___

Remission
(63)
Mild
(28.8)
Moderate
to Severe
(8.2)
Remission
(50)
Mild (29)
Moderate
(21)
Severe (0)
___

Remission
(75.7)
Mild
(24.3)
Moderate
to Severe
(29)
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Author
(Year)

Country

Study
Design

Sample
Size
Total
(n)

Szigethy et
al (2014b)
&
Szigethy et
al. (2015)

USA

RCT

I = 110
C=
107
n = 217

Age
Range;
Mean
Age
(SD)
9-17;
14.3
(2.5)

Gender
(%)

Ethnicity (%)

Disease
Type
(%)

F (53)
M (47)

White/Caucasian
(89.4)

CD
(74.2)
UC
(25.8)

Disease
Severity
(%)

___

Note: Methodology/Study Design: control group (C); intervention group (I); non-randomized
controlled trial (NRCT); randomized controlled trial (RCT). Disease Type: Crohn’s Disease
(CD); Indeterminant Colitis (IC); Inflammatory Bowel Disease (IBD); Ulcerative Colitis (UC).
* Stapersma et al. (2018) conducted separate analyses for youth and young adult age groups (i.e.., 10-20
years, 21-25 years).
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Table 2
Intervention Characteristics
Author
(Year)

Intervention Aims

Format

Grootenhuis
et al. (2009)

Psychoeducational
CBT-based group
intervention that aimed
to strengthen coping
and improve HRQOL
through teaching the
active use of coping
skills.
Brief SLCBT
intervention that aimed
to reduce parent
solicitousness, increase
children’s adaptive pain
coping efficacy beliefs
and use of adaptive
coping strategies,
improve quality of life,
reduce functional
disability, and decrease
health care utilization
and school absenteeism.
CBT intervention that
aimed to effectively
help patients cope with
IBD symptoms,
restructure maladaptive
thoughts, use
distraction techniques
and communication
skills.

Adolescent
group

TAPS + IBD is a
disease-specific CBT
protocol aimed to treat
youth with comorbid
IBD and anxiety
disorders. This
intervention
concurrently addresses
anxiety (including IBDspecific anxiety) and
disease management
among children and
adolescents with IBD.

Independent
adolescent
and parent
sessions with
some family
involvement

Levy et al.
(2016)

McCormick
et al. (2010)
&
ReedKnight et al.
(2012)

Reigada et
al. (2015b)

Number of
Sessions,
Frequency,
& Duration
6 weekly
sessions

Mode of
Delivery

Setting

Control or
Comparison
Group

In-person

Medical
clinic

Wait-list

Joint parentchild
sessions;
Each met
independently
with provider
for 5-mins at
the end of
sessions

3 weekly
sessions;
Mean
session
length of
70.68-mins
(SD =
14.31)

In-person

Medical
clinic or
family’s
home

ES

Independent
adolescent
and parent
groups

1-day (6hrs) inperson
intervention
followed by
a
6-week
web-based
component
(30-mins
online
weekly chat
discussion)
13 weekly
sessions
(60-mins)
2 booster
sessions
(60-mins)
3 parent
sessions
(60-mins)

In-person
and
webbased

Medical
clinic (inperson
session)
& home
(webbased
sessions)

Wait-list

In-person

Medical
clinic or
urban
college

SNDT
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Author
(Year)

Intervention Aims

Format

Stapersma et
al. (2018)
&
Stapersma et
al. (2020)

Adapted the PASCETPI intervention (a
disease-specific CBT
protocol) to treat youth
with comorbid IBD and
subclinical anxiety
and/or depressive
symptoms. This
intervention aimed to
reduce anxiety and
depressive symptoms
and improve HRQOL.
PASCET-PI is a
disease-specific CBT
protocol developed to
treat adolescents with
IBD and depression
with the aim to reduce
depressive
symptomology.

Independent
adolescent
and parent
sessions

PASCET-PI is a
disease-specific CBT
protocol developed to
treat adolescents with
IBD. This intervention
was compared to SDNT
to evaluate treatment
efficacy with the aim of
a comparative reduction
in depressive symptom
severity and improved
health-related
adjustment and disease
activity.

Szigethy et
al. (2007)
&
Thompson
et al. (2012)

Szigethy et
al (2014b)
&
Szigethy et
al. (2015)

Number of
Sessions,
Frequency,
& Duration
10 weekly
sessions
3 booster
sessions
(monthly;
by
telephone)
3 parent
sessions

Mode of
Delivery

Setting

Control or
Comparison
Group

In-person
(6
sessions)
and
telephone
(4
sessions)

Medical
clinics
(6)

TAU

Independent
adolescent
and parent
sessions.

9 to 11
weekly
sessions
(60-mins)
3 parent
sessions

Medical
clinic

TAU

Independent
adolescent
sessions with
family
involvement
at the end

Up to 12
weekly
sessions
(45-mins)
3 parent
sessions

In-person
and
telephone
(more
than 1/3
of
sessions
via
telephone)
In-person
and
telephone
(more
than 1/2
of
sessions
via
telephone)

Medical
clinic

SNDT

Note: Interventions & Control/Comparison Groups: Cognitive-Behavioral Therapy (CBT);
Education Support (ES); Primary and Secondary Control Enhancement Training for Physical
Illness (PASCET-PI); Social Learning Cognitive-Behavioral Therapy (SLCBT); Supportive
Non-Directive Therapy (SNDT); Treatment as Usual (TAU); Treatment of Anxiety and Physical
Symptoms for Inflammatory Bowel Disease (TAPS + IBD).
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Table 3
Treatment Outcomes and Main Findings
Author
(Year)

Time
Points
Assessed

Outcomes
Assessed

Measuring
Main Findings
Instruments

Grootenhuis
et al. (2009)

Baseline
Postimmediate
Follow-up
6-8 mo

Depression
Anxiety
HRQOL

CBCL
STAI-C
DUX-25

Levy et al.
(2016)

Baseline
Postimmediate
Follow-up
3, 6, 12 mo

Depression
Anxiety
HRQOL
Physical/Somatic
Disease Activity

CDI
MASC
IMPACT-III
FDI; PRI
PUCAI;
PCDAI

McCormick
et al. (2010)
&
Reed-Knight
et al. (2012)
Reigada et al.
(2015b)

Baseline
Postimmediate
Follow-up 6
mo
Baseline
Postimmediate
Follow-up 3
mo
Baseline
Postimmediate
Follow-up 6
& 12 mo

Physical/Somatic

API; CSI

Anxiety
Disease Activity

ADIS-IV-P/C;
IBD-SAS
PUCAI;
PCDAI

TAPS + IBD intervention was associated
with significantly greater reductions in
IBD-specific anxiety post-treatment and at
three-month follow-up.

Depression
Anxiety
HRQOL
Disease Activity

CDI
SCARED
IMPACT-III
PUCAI;
PCDAI

Baseline
Postimmediate
Follow-up
at 6 & 12
mo

Depression
Disease Activity

CDI; K-SADSPL
CSK; PCDAI

Participants in both the PASCET-PI
intervention and TAU control groups
improved in their symptoms of depression,
anxiety, and HRQOL. Results showed no
difference between the PASCET-PI and
TAU group post treatment and at 12-month
follow-up.
The PASCET-PI intervention group
showed significantly greater improvement
in depressive severity than the comparison
group. The impact on depressive severity
was not maintained at six- or 12- month
follow-up. No significant differences
between groups for number of depressive
symptoms.

Stapersma et
al. (2018)
&
Stapersma et
al. (2020)
Szigethy et
al. (2007)
&
Thompson et
al. (2012)

Significant improvement in body image, a
domain of HRQOL, although no additional
effects found on other subscales of
HRQOL. No intervention effects found for
anxiety and behavioral-emotional
outcomes.
Significant overall treatment effect found
for child-reported IBD-specific quality of
life in the SLCBT intervention group. No
significant treatment effects for child- or
parent-reported depression or anxiety. No
significant effect on reducing symptoms of
functional disability. Improvements over
time on pain responses were found,
although the improvements were similar
between the two conditions.
Significant improvements in adolescents’
somatic symptoms following treatment in
the intervention group, although betweengroup comparisons were not significant.
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Author
(Year)

Time
Points
Assessed

Outcomes
Assessed

Measuring
Main Findings
Instruments

Szigethy et al
(2014b)
&
Szigethy et
al. (2015)

Baseline
Postimmediate

Depression
HRQOL
Disease Activity

CDI; K-SADSPL; CDRS-R
IMPACT-III
PUCAI;
PCDAI

Both PASCET-PI and SNDT interventions
resulted in significant reductions in
depressive symptoms, although the
difference between the two treatments was
not significant. Compared to SNDT,
PASCET-PI was associated with a greater
reduction in IBD activity. Secondary
analyses indicated that of the participants
in the CBT intervention group, patients
with Crohn’s disease with a somatic
depressive subtype and active disease
showed greater improvement in disease
activity.

Note: Measuring Instruments: Depression: Child Behavior Check List (CBCL); Child
Depression Inventory (CDI); Children’s Depression Rating Scale–Revised (CDRS-R); KiddieSchedule for Affective Disorders and Schizophrenia – Present and Lifetime Version (K-SADSPL). Anxiety: Anxiety Disorders Interview Schedule for DSM-IV: Parent and Child Versions
(ADIS-IV-P/C); IBD-Specific Anxiety Scale (IBD-SAS); Multidimensional Anxiety Scale for
Children (MASC); Screen for Child Anxiety- Related Emotional Disorders (SCARED); StateTrait Inventory for Children (STAI-C). HRQOL: Dutch Children’s AZL/TNO Quality of Life
Questionnaire (DUX-25); IMPACT-III Questionnaire (IMPACT-III). Physical/Somatic
Symptoms: Abdominal Pain Index (API); Child Somatization Inventory (CSI); Functional
Disability Inventory (FDI); Pain Response Inventory (PRI). Disease Activity/Severity: Clinical
Score of Kozarek (CSK); Pediatric Crohn’s Disease Activity Index (PCDAI); Pediatric
Ulcerative Colitis Activity Index (PUCAI).
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Figures
Figure 1
Prisma Flow Diagram

Screening

Identification

Identification of studies via databases and registers

Records identified from:
Databases (n = 478)
PsycInfo (n = 241)
PubMed (n = 237)

Records removed before
screening:
Duplicate records removed
(n = 10)

Records screened
(n = 468)

Records excluded from
title/abstract (n = 429)

Reports sought for retrieval
(n = 39)

Reports not retrieved
(n = 0)

Included

Reports assessed for eligibility
(n = 39)

Studies included in review
(n = 11)
Original Studies (n = 7)
Follow-ups (n = 4)

Reports excluded: (n = 28)
Reason 1: Uncontrolled studies (n = 8)
Reason 2: Adults only (n = 6)
Reason 3: Parents only (n = 3)
Reason 4: No separate analysis between
adolescents and young adults (n = 3)
Reason 5: Other Primary Outcomes (n = 8)
Medication Adherence (n = 5)
Transition (n = 2)
Shared Decision Making (n = 1)
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Decision Codes:
Include/Continue to Abstract/Continue to Full Text/Undecided/Exclude (IN/CFT/CAB/UN/EX)
Criteria Codes:
(Is the Criteria Met?) Yes/Unclear/No (Y/UC/NO)
PHASE 1 (Red): Title/Keywords/Abstract (Screening)
PHASE 2 (Blue): Full-Text Review (Eligibility)
PHASE 3 (Green): Final Decision (Selection)
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INDIVIDUAL STUDY QUALITY APPRAISAL FORM FOR SYSTEMATIC REVIEWS
Developed by Shelly P. Harrell, Ph.D., Pepperdine University
Author(s) and Year: ____________________________________________________________ Study ID#___________
Methodology:

Quantitative

Mixed Methods

Specific Design/Inquiry Approach: ___________________________________________________________________
RATING SCALE:

Strong=3

Good/Adequate=2

Weak=1

N/A

1.

Strength of Literature Foundation and Rationale for Study: _______
(POSSIBLE CONSIDERATIONS: current and relevant references, background literature sufficiently comprehensive,
Need/Rationale for study clearly stated, etc.)

2.

Clarity and specificity of Research Aims/Objectives/Questions/Hypotheses: _______

3.

Quality of research design or methodological approach: _______
GENERAL CONSIDERATIONS: provides rationale for design chosen, appropriateness for research questions,
clear description of design and methodological approach, strength of design characteristics utilized, internal
and external validity considered in design; potential confounds identified and addressed in some way,
specific design-based “risk of bias” criteria considered such as randomization, blinding

4.

Sample Selection and Characteristics: _______
GENERAL CONSIDERATIONS: detailed description of sample characteristics, adequacy of sample characteristics in the
context of research aims, detailed description of recruitment/selection of participants; rationale provided for sample
size; inclusion and exclusion criteria indicated as relevant, representativeness of sample, adequacy of sample size in
context of design, extent of selection or sample bias

5.

Data Collection Tools (Scales, Observation, Interviews, etc.): _______
GENERAL CONSIDERATIONS: rationale for selection, appropriateness for assessing variables, development
of study-specific tool or process clearly described, piloting, pretesting, psychometric properties (reliability, validity,
utility) reported, adequacy of psychometric properties, normative or standardization data described

6.

Data Collection Processes: _______
POSSIBLE CONSIDERATIONS: data collection procedures clearly described in sufficient detail, intervention strategies
and implementation described in detail, quality of data collected, design-specific considerations such as attrition in
RCTs, saturation in grounded theory

7.

Analysis and Presentation of Data: _______
GENERAL CONSIDERATIONS: appropriateness of analysis for research questions and type of data; results presented
clearly and comprehensively; usefulness and clarity of any tables, graphs, and charts, power and effect size reported;
relevant statistics reported clearly; effective use of tables

8.

Discussion of Study Limitations: _______
GENERAL CONSIDERATIONS: identifies and discusses limitations in the context of design/strategy utilized, addresses
various forms of bias, internal validity, external validity (generalizability), ecological validity

9.

Consideration of culture and diversity: _______
POSSIBLE CONSIDERATIONS: attention to diversity within sample, includes culturally appropriate methods
and tools, avoids biased language, uses appropriate terminology

OVERALL RATING:

EXEMPLARY
(e.g., all “3”s)

STRONG
(e.g., mostly “3”s)

GOOD/ADEQUATE
(e.g., mostly “2”s).

WEAK
(e.g., mostly “1”s)
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Graduate & Professional Schools Institutional Review Board
Graduate & Professional Schools Institutional Review Board
March 29, 2022
Protocol #: 32922
Project Title: Treating Gut Feelings: Psychological Treatment for Pediatric Inflammatory Bowel
Disease.
Dear Venus:
Thank you for submitting a “GPS IRB Non-Human Subjects Notification Form” for Treating Gut
Feelings: Psychological Treatment for Pediatric Inflammatory Bowel Disease project to
Pepperdine University’s Institutional Review Board (IRB) for review. The IRB has reviewed your
submitted form and all ancillary materials. Upon review, the IRB has determined that the above
titled project meets the requirements for non-human subject research under the federal
regulations 45 CFR 46.101 that govern the protection of human subjects.
Your research must be conducted according to the form that was submitted to the IRB. If
changes to the approved project occur, you will be required to submit either a new “GPS IRB
Non-Human Subjects Notification Form” or an IRB application via the eProtocol system
(httpw://irb.pepperdine.edu) to the Institutional Review Board.
A goal of the IRB is to prevent negative occurrences during any research study. However,
despite our best intent, unforeseen circumstances or events may arise during the research. If an
unexpected situation or adverse event happens during your investigation, please notify the IRB
as soon as possible. We will ask for a complete explanation of the event and your response.
Other actions also may be required depending on the nature of the event. Details regarding the
timeframe in which adverse events must be reported to the IRB and documenting the adverse
event can be found in the Pepperdine University Protection of Human Participants in Research:
Policies and Procedures Manual at https://community.pepperdine.edu/irb/policies/.
Please refer to the protocol number denoted above in all further communication or
correspondence related to this approval.
On behalf of the IRB, we wish you success in this scholarly pursuit.
Sincerely,
Institutional Review Board (IRB)
Pepperdine University
cc:

Mrs. Katy Carr, Assistant Provost for Research
Dr. Judy Ho, Graduate School of Education and Psychology IRB Chair

